[Effects of metformin therapy on serum CA125 levels and its related factors in type 2 diabetics].
To explore the effects of metformin therapy on serum carbohydrate antigen 125 (CA125) levels and its related factors in type 2 diabetics with normal liver and kidney function. Serum CA125 level was measured and compared for a total of 1 136 type 2 diabetics. They were assigned into groups according to gender, age and body mass in dex (BMI) and subgroups according to metformin dosing. Associations between CA125 and other variables were assessed with Spearman or Pearson's correlation and multiple stepwise regression analysis. The CA125 level of metformin group was significantly lower than that of non-metformin group (10.51(8.18, 13.80) vs 11.93(9.05, 15.52) U/ml, P < 0.01) . The CA125 levels of males aged 30-39 and 50-59 as well as females aged over 50 remarkably decreased after metformin dosing (all P < 0.05). The difference of CA125 level between metformin and non-metformin groups in patients with normal BMI and obese females reached statistical significance (all P < 0.05). The correlation analysis showed that serum CA125 level was positively associated with gender, HbA1c, glycated serum albumin, triglyceride, total cholesterol (P < 0.05), but negatively with metformin and creatinine (P < 0.01). Multiple stepwise regression analysis further revealed that GA, metformin dosing, gender and total glycerides were independent influencing factors of CA125 concentrations (all P < 0.05). Metformin dosing is an independent associated factor of serum CA125 levels reduction in type 2 diabetics, especially females.